New product: LEMTRADA (alemtuzumab) 12 mg concentrate for solution for infusion

Alemtuzumab (given as two IV infusion courses 12 months apart) is indicated for adults with relapsing–remitting MS with active disease defined by clinical or imaging features. Patients must be given a Patient Alert Card and Patient Guide and be informed about risks of treatment.

NICE has issued guidance recommending alemtuzumab as an option, within its marketing authorisation, for treating adults with active relapsing–remitting multiple sclerosis (TA 312; May 2014). Please see the link below for details.

 

Alemtuzumab was previously approved in the EU (under the trade name MabCampath®) for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL), but its marketing authorisation was withdrawn voluntarily in 2012.